Baker Avenue Asset Management, LP Vaxcyte, Inc. Transaction History
Baker Avenue Asset Management, LP
- $5.03 Billion
- Q3 2025
A detailed history of Baker Avenue Asset Management, LP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Baker Avenue Asset Management, LP holds 13,143 shares of PCVX stock, worth $635,332. This represents 0.01% of its overall portfolio holdings.
Number of Shares
13,143
Previous 13,143
-0.0%
Holding current value
$635,332
Previous $427,000
10.77%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding PCVX
# of Institutions
322Shares Held
134MCall Options Held
408KPut Options Held
116K-
Janus Henderson Group PLC London, X013.1MShares$633 Million0.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.3MShares$596 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$578 Million7.4% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$480 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.32MShares$402 Million0.18% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.87B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...